Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers develop first mouse model of epithelial ovarian cancer

17.03.2003


Fox Chase Cancer Center researchers and their colleagues have developed a mouse model of the most prevalent and deadly form of human ovarian cancer -- epithelial ovarian cancer. The mouse model provides a better opportunity to study the cause of ovarian cancer, examine the genes involved and test preventive, diagnostic and treatment approaches that could be applied to human ovarian cancer.



"These transgenic mice offer us a valuable scientific tool that never before has been available to ovarian cancer researchers," explained Fox Chase Cancer Center’s Denise C. Connolly, Ph.D., corresponding author of the study, which appears in the March 15, 2003, issue of Cancer Research, a journal of the American Association for Cancer Research.

The mice engineered by Connolly and her colleagues develop epithelial ovarian cancer in both ovaries. This cancer arises in the surface, or epithelial, cells of the ovaries. The mouse model was made by introducing a genetically engineered DNA fragment into fertilized mouse eggs prior to their embryonic development. The fragment is a combination of a gene specific promoter and a potent oncogene. The oncogene, Simian virus 40 T antigen, triggers cancer development. The promoter is derived from a gene (Mullerian inhibitory substance type II receptor) that signals the expression of a specific protein found in cells covering the ovaries.


"It was critical to attach the oncogene to a regulator that would limit the cancer-causing gene’s expression to the ovary, including the epithelial ovarian cells," explained Connolly. "Using this strategy, we have generated transgenic animals that develop epithelial ovarian cancer that spreads to the peritoneal organs, similar to human epithelial ovarian cancers."

In humans, epithelial ovarian cancer is diagnosed in approximately 23,000 women each year. In 2003, it is estimated that 14,000 women will die of the disease, making it the fifth most common cancer in women in the United States.

Early detection of these tumors is challenging because there is no standard screening available for the disease. When ovarian cancer is diagnosed at early stages, the survival rate approaches 90 percent. However, the vast majority of cases of ovarian cancer are not identified until late stages, when the survival rate drops to only 30 to 40 percent.

"The development of mouse models of epithelial ovarian cancer may significantly facilitate advances in early detection and treatment of the disease," said Thomas C. Hamilton, Ph.D., senior member of the medical science division at Fox Chase Cancer Center and leader of the ovarian cancer research program. "Models such as this are critical to cancer research because they will allow us to study the progression of ovarian cancer from the very earliest stages to advanced disease.

"The next step is to test chemotherapeutic and chemopreventive agents that we hope will translate into meaningful improvements in the prevention and treatment of ovarian cancer. We’ll also study the relevant oncogenes and tumor-suppressor genes for their ability to allow or trigger the cancer to develop," Hamilton added.

Other contributing researchers include Rudi Bao, M.D., Kasie C. Stephens, Timothy W. Poole, Ph.D., Xiang Hua and Skye S. Harris of Fox Chase Cancer Center; Alexander Yu. Nikitin, M.D., Ph.D., of Cornell University; and Barbara C. Vanderhyden, Ph.D., of the University of Ottawa.

Funding for this research is provided in part by a grant from the National Cancer Institute’s Mouse Models of Human Cancers Consortium (MMHCC), of which Hamilton is a member. Mouse models that recapitulate many aspects of the genesis, progression and clinical course of human cancers are valuable resources to cancer researchers engaged in a variety of basic, translational, clinical and epidemiological investigations.

MMHCC is a collaborative program designed to derive and characterize mouse models and to generate resources, information and innovative approaches to the application of mouse models in cancer research.



Additional grants supporting Dr., Hamilton’s research were received from the National Institutes of Health, the National Cancer Institute Specialized Program of Research Excellence for ovarian cancer, the Commonwealth of Pennsylvania, Edgar Astrove, the Adler Foundation and the Evy Lessin Fund.

Fox Chase Cancer Center, one of the nation’s first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center’s web site at http://www.fccc.edu or call 1-888-FOX CHASE.

Karen Mallet | EurekAlert!
Further information:
http://www.fccc.edu

More articles from Health and Medicine:

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

nachricht Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Gran Chaco: Biodiversity at High Risk

17.01.2018 | Ecology, The Environment and Conservation

Only an atom thick: Physicists succeed in measuring mechanical properties of 2D monolayer materials

17.01.2018 | Physics and Astronomy

Fraunhofer HHI receives AIS Technology Innovation Award 2018 for 3D Human Body Reconstruction

17.01.2018 | Awards Funding

VideoLinks
B2B-VideoLinks
More VideoLinks >>>